Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + oxaliplatin versus paclitaxel + carboplatin with radiotherapy in esophageal cancer
IRCT20170306032913N4Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine, oxaliplatin, paclitaxel and carboplatin in esophageal cancer (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Pathologic response rate, Clinical response rate and 6 more. Started Mar 2017; status: completed.
02
Drugs
capecitabineoxaliplatinpaclitaxelcarboplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on IRCT20170306032913N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170306032913N4.